Coopervision receives fda approval of misight for the treatment of myopia in children

Coopercompanies announced that coopervision has received u.s. food and drug administration (fda) approval of its misight® 1 day contact lens1, indicated to slow the progression of myopia (nearsightedness or short-sightedness) when initially prescribed for children 8-12 years old.  misight® 1 day has been scientifically proven to reduce myopic progression by up to 59%. this is the first fda approved myopia management contact lens and is expected to be available in the u.s. beginning in march of 2020.  misight (omafilcon a) daily wear single use soft contact lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with = 0.75 diopters of astigmatism. the lens is to be discarded after each removal. when compared to the children in the control group wearing a single vision 1-day contact lens.
COO Ratings Summary
COO Quant Ranking